Istituto Nazionale Tumori

What Istituto Nazionale Tumori does

Istituto Nazionale Tumori "Fondazione Pascale" is a public Italian oncology hospital and research institute headquartered in Naples, designated as an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) under the Ministry of Health. It is described as one of the most significant oncology realities in Southern Italy, delivering comprehensive cancer care including diagnosis, surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, stem cell transplantation, and palliative care, alongside clinical trials and translational research. Operations span the main Naples campus (Via Mariano Semmola 52), the Presidio Ospedaliero Cardinale Ascalesi secondary site, and the Mercogliano research laboratories.

The institute's core technology is a translational research department (Dipartimento di Ricerca Traslazionale a supporto dei percorsi oncologici) that explicitly converts laboratory scientific discoveries into clinical applications for oncology patients. The technology portfolio includes MRg-HIFU (Magnetic Resonance-guided High Intensity Focused Ultrasound) for non-invasive tumor ablation, Next Generation Sequencing for biomarker research, robotic platforms for pre-clinical and clinical research, a digital "Paziente Elettronico" patient management platform, and the Roche Navify Tumour Board decision-support platform used within the MITO gynecological oncology research group. Product/services catalogue also enumerates a Stem Cell Transplant and Advanced Cellular Therapies unit, clinical trials infrastructure, and dedicated scientific directorate units covering epidemiology, biostatistics, internationalization of research, and research monitoring/quality assurance.

The business model is that of a public-law IRCCS operating under the Italian National Health Service (Servizio Sanitario Nazionale). Revenue is delivered through SSN tariffs and capitation for healthcare delivery plus dedicated Ministry of Health IRCCS research funding and competitive European grants (e.g., the Horizon Europe REMEDi4ALL project, EUR 23M over 5 years). Patient access flows through general practitioner and specialist referral within the Campania regional network and the Rete Oncologica Campana; services carry only standard national co-payment (ticket) fees, with no commercial pricing. Customer segments are (1) oncology patients across Campania and Southern Italy as the primary segment, and (2) healthcare professionals and researchers nationally and internationally engaged through trials, training, and scientific conferences. The institute collaborates with international networks including OECI, EATRIS, and Alleanza Contro il Cancro.

Name

Istituto Nazionale Tumori

Legal name

IRCCS Istituto Nazionale Tumori Fondazione G. Pascale

Website

https://newportal.istitutotumori.na.it

Company type

Private

Founded year

1933

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Istituto Nazionale Tumori "Fondazione Pascale" is a public Italian IRCCS oncology hospital and translational research center in Naples, delivering comprehensive cancer care, clinical trials, and laboratory-to-clinic research programs to oncology patients across Southern Italy, funded through the Italian National Health Service.

Ownership category

akta.pro rank

Product category

Cancer hospital and translational research services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Medical Laboratories (621511)

SIC

Services-Health Services (8000)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Oncology hospital services
• Cancer treatment
• Translational research
• Clinical trials oncology
• Radiotherapy services

Headquarters

HQ city

Naples

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. National Health Service Funding: Public healthcare institution funded through the Italian National Health Service (Servizio Sanitario Nazionale), operating as an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) with public funding for both healthcare delivery and research activities

Distribution channels1 record

Marketing channels6 records

Core offering

Istituto Nazionale Tumori Fondazione Pascale is a public IRCCS oncology hospital and research institute delivering comprehensive cancer care (diagnosis, surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, stem cell transplantation, palliative care) alongside translational research and clinical trials. It operates as a reference cancer center for the Campania region within the Italian National Health Service (SSN), combining patient care, research, and advanced treatment technologies such as MRg-HIFU and Next Generation Sequencing.

Product overview

Istituto Nazionale Tumori 'Fondazione Pascale' is an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) public research hospital specializing in oncology. It operates as a comprehensive cancer center offering translational research, clinical care, and advanced therapies. The institution provides a broad portfolio of services including patient care (outpatient clinics, day hospital, ordinary hospitalization), specialized research departments (translational research, epidemiology, molecular biology), clinical trials, stem cell transplantation, and advanced technologies such as MRg-HIFU for non-invasive tumor treatment and next-generation sequencing for biomarker research. The research mission is translational, verifying the transformation of laboratory discoveries into clinical applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncology Clinical Care and Hospitalization Comprehensive cancer diagnosis, hospitalization, surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, palliative care, and follow-up services provided to oncology patients under the Italian National Health Service (SSN).
• Stem Cell Transplantation and Advanced Cellular Therapies Unit Stem cell transplantation and advanced cellular therapies for cancer treatment provided to oncology patients, inaugurated as a dedicated department in July 2025.
• MRg-HIFU (Magnetic Resonance-guided High Intensity Focused Ultrasound) Non-invasive targeted tumor ablation using high-intensity focused ultrasound guided by magnetic resonance imaging, offering an alternative to invasive surgical oncology treatments.
• Translational Research Department (Dipartimento di Ricerca Traslazionale a supporto dei percorsi oncologici) Translational research function bridging laboratory scientific discoveries with clinical applications in oncology, supporting the integration of basic research with clinical practice to accelerate scientific discoveries into medical applications.
• Clinical Trials (Studi Clinici) Clinical trials and studies for cancer treatment and research, providing oncology patients access to experimental therapies and supporting pharmaceutical and academic research.
• Next Generation Sequencing (NGS) Biomarker Service Advanced genomic sequencing service supporting precision oncology biomarker research and molecular diagnostics, including SARS-CoV-2 detection applications.
• Patient Digital Platform (Paziente Elettronico) Digital platform enabling patient management and care coordination across oncology services, supporting digital interaction between patients and the healthcare team.
• Robotic Platforms for Preclinical and Clinical Research Automated robotic laboratory systems supporting preclinical and clinical research activities and therapeutic development within the institute's research infrastructure.

Quantifiable outcome

• Served as one of the most significant oncology centers in Southern Italy providing comprehensive cancer care

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Nine partnerships are on record, tiered core and minor.

• Alleanza Contro il Cancro (ACC)coreStrategic or Co-development Partner · 10 September 2026Hosting the 11th Annual Meeting of Alleanza Contro il Cancro in Naples (September 10-12, 2026), organized in collaboration with the National Oncology Network of the Italian Ministry of Health. The event focuses on 'New Technologies and Strategies to Fight Cancer'.
• REMEDi4ALL ConsortiumcoreStrategic or Co-development Partner · 1 September 2022European project funded under Horizon Europe for 23 million euros (with over 4 million to Italian partners), aiming to reposition already approved drugs for new therapeutic indications, particularly pancreatic cancer, COVID, and rare diseases. Italian partners include Istituto Nazionale Tumori Fondazione Pascale, Istituto Mario Negri, Istituto Ortopedico Rizzoli, and Dompé farmaceutici Spa. Led by EATRIS European infrastructure for translational medicine. Duration: 5 years.
• Lo Sportello dei Sogni (Association)minorGTM or Marketing Partner · 27 December 2021Agreement with the non-profit association 'Lo Sportello dei Sogni' to fulfill small wishes of oncology patients through the institute's psycho-oncology service, creating a 'Sogno Sospeso' (suspended dream) program similar to the suspended coffee concept.
• RochecoreTechnology or Integration · 29 October 2021Partnership with Roche for the use of the Navify Tumour Board platform for research activities of the MITO group, aiming at better classification of patients with Gynecological Neoplasms. Includes deliberation and sponsorship contract.
• EATRIS (European Research Infrastructure for Translational Medicine)coreStrategic or Co-development PartnerEuropean infrastructure for translational medicine of which the three Italian public research institutes (including INT Pascale) are members. Leads the REMEDi4ALL consortium.
• Dompé farmaceutici SpaminorStrategic or Co-development PartnerItalian pharmaceutical company partner in the REMEDi4ALL European project for drug repositioning in oncology, rare diseases, and COVID-19 therapeutics.
• OECI (Organization of European Cancer Institutes)coreStrategic or Co-development PartnerThe institute is a member of OECI, a non-governmental foundation founded in 1979 in Vienna, now based in Brussels, uniting 68 cancer treatment and research institutes across Europe.
• Istituto Di Ricerche Farmacologiche Mario NegricoreStrategic or Co-development PartnerResearch partner in the REMEDi4ALL European project consortium, along with Istituto Nazionale Tumori Fondazione Pascale, Istituto Ortopedico Rizzoli, and Dompé farmaceutici Spa.
• Istituto Ortopedico RizzolicoreStrategic or Co-development PartnerResearch partner in the REMEDi4ALL European project consortium, along with Istituto Nazionale Tumori Fondazione Pascale, Istituto Mario Negri, and Dompé farmaceutici Spa.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - INT: Italian national cancer institute and IRCCS specializing in oncology research and treatment. Direct peer in scope, mission, and public funding model, frequently cited alongside Pascale in national oncology rankings.
• Ospedale Policlinico San Martino IRCCS: Genova-based IRCCS hospital with a strong oncology department, clinical trials unit, and translational research programs. Comparable as a public Italian research hospital integrating oncology care with bench-to-bedside science under SSN funding.
• Istituto Oncologico Veneto (IOV) IRCCS: Veneto-based IRCCS oncology center delivering multidisciplinary cancer care and research. Directly comparable as a regional Italian specialty oncology institution with hospital, research, and clinical trial functions under public governance.
• IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori: Public Italian IRCCS oncology center in Meldola focused on cancer research and treatment. Comparable as a regionally anchored oncology research hospital that combines clinical care, translational research, and clinical trials within the SSN framework.
• Istituto Europeo di Oncologia (IEO): Major Italian oncology center in Milan with a translational research model analogous to Pascale's. Comparable as a leading Italian cancer hospital combining clinical care with molecular and clinical research, targeting similar patient segments and competing for clinical trial allocations.
• Istituto Nazionale dei Tumori (INT) - Milan: Italy's other national oncology IRCCS based in Milan, providing comprehensive cancer care and translational research under the SSN. Directly comparable as a public IRCCS oncology specialty hospital with parallel research and clinical trial missions and competing for the same national funding and patient referrals.

Broad incumbents

• The Royal Marsden NHS Foundation Trust: UK-based specialist cancer hospital and research center with strong ties to the Institute of Cancer Research. Comparable as a public-sector specialty oncology hospital that integrates clinical care with translational and clinical research.
• Netherlands Cancer Institute (NKI): Dutch comprehensive cancer center integrating hospital care with fundamental and translational research. Comparable as a European specialty oncology hospital with a dual clinical-research mandate and strong pharmaceutical and EU research collaborations.
• Vall d'Hebron Institute of Oncology (VHIO): Barcelona-based oncology research institute embedded within the Vall d'Hebron University Hospital. Comparable as a translational oncology research center partnering with a public hospital to deliver clinical trials and precision oncology programs in a European public healthcare system.
• Gustave Roussy: Leading European comprehensive cancer center in Villejuif, France, combining oncology care, translational research, and clinical trials at large scale. Comparable as a European oncology specialty hospital network with research-hospital dual mandate, serving as a benchmark for translational oncology scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/istitutotumori
• Facebookfacebook.com/istitutotumoripascale

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Istituto Nazionale Tumori